Business Description
Relmada Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US75955J4022
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.88 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 4.1 | |||||
3-Year EPS without NRI Growth Rate | 4.9 | |||||
3-Year FCF Growth Rate | 1.3 | |||||
3-Year Book Growth Rate | -24 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38.65 | |||||
9-Day RSI | 38.5 | |||||
14-Day RSI | 39.25 | |||||
6-1 Month Momentum % | 46.32 | |||||
12-1 Month Momentum % | 31.79 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 8 | |||||
Quick Ratio | 8 | |||||
Cash Ratio | 7.9 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.6 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -87.69 | |||||
ROA % | -80.03 | |||||
ROIC % | -11715.21 | |||||
ROCE % | -92.05 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.24 | |||||
Price-to-Tangible-Book | 1.24 | |||||
EV-to-EBIT | -0.1 | |||||
EV-to-EBITDA | -0.1 | |||||
EV-to-FCF | -0.2 | |||||
Price-to-Net-Current-Asset-Value | 1.25 | |||||
Price-to-Net-Cash | 1.26 | |||||
Earnings Yield (Greenblatt) % | -1000 | |||||
FCF Yield % | -48.5 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Relmada Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -3.033 | ||
Beta | -0.77 | ||
Volatility % | 94.52 | ||
14-Day RSI | 39.25 | ||
14-Day ATR (€) | 0.161279 | ||
20-Day SMA (€) | 3.691 | ||
12-1 Month Momentum % | 31.79 | ||
52-Week Range (€) | 2.18 - 6.35 | ||
Shares Outstanding (Mil) | 30.17 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Relmada Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Relmada Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Relmada Therapeutics Inc Frequently Asked Questions
What is Relmada Therapeutics Inc(STU:4E2)'s stock price today?
When is next earnings date of Relmada Therapeutics Inc(STU:4E2)?
Does Relmada Therapeutics Inc(STU:4E2) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |